Is Cullinan Therapeutics, Inc. (CGEM) a Buy, Sell, or Hold?

Buy Sell Hold Not Sure

Enter your email address below for free access to our Cullinan Therapeutics, Inc. (CGEM) research center and poll results.

NASDAQ : CGEM

Cullinan Therapeutics, Inc.

$19.1 USD

$0.82 (4.49%)

Volume: 278.39K
Average Volume: 933.5K
Market Capitalization: $1.17B
P/E Ratio: -5.67
Dividend Yield: 0.00%
Price Target: $33.50

Year High: $19.43
Year Low: $5.68
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $8.42

Price Target and Rating

Average Stock Price Forecast	$33.50
High Stock Price Forecast	$39.00
Low Stock Price Forecast	$28.00
Forecast Upside/Downside	-42.99%
Consensus Rating	Sell
Rating Score(0-5)	2
Research Coverage	8 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$3.72
Trailing P/E Ratio	-5.67
PEG Ratio	-1.80
P/E Growth	-1.80
Net Income	-$219.88M
Net Margin	0.00%
Pretax Margin	0.00%
Return on Equity	-52.89%
Return on Assets	-56.27%

Financials Score

AltmanZ Score	12.48
Piotroski Score	1.00
Working Capital	301.35M
Total Assets	363.79M
Ebit	-208.72M
Market Cap	1.12B
Total Liabilities	42.03M

Company Executives

Name	Title
Nadim Ahmed	President, Chief Executive Officer & Director
Jacquelyn L. Sumer	Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Mary Kay Fenton	Chief Financial Officer
Rose Weldon	Senior Vice President of Corporate Affairs
Nicholas Smith	Head of Investor Relations
Corinne Savill	Chief Business Officer
Jennifer Michaelson	Chief Scientific Officer
Patrick A. Baeuerle	Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
Steve Andre	Chief Human Resources Officer
Jeffrey Jones	Chief Medical Officer

About Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts. ...

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

2026-08-06 07:00:00

CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

2026-07-28 07:00:00

CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced positive feedback from the U.S. Food and Drug Administration (FDA) following an End-of-Phase 1 (EOP1) meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia (AML).

Cullinan Therapeutics: Heading Toward Paydirt

2026-06-11 11:41:04

Cullinan Therapeutics remains a compelling buy as zipalertinib approaches a key FDA decision for EGFR exon 20 insertion NSCLC. Zipalertinib demonstrates promising efficacy, including CNS activity and responses post-amivantamab, with pivotal phase 3 REZILIENT3 data expected later this year. CGEM's diversified pipeline in oncology and immunology, strong cash reserves, and operational runway into 2029 support continued optimism.

Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcript

2026-06-10 17:32:10

Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcript

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

2026-06-10 07:30:00

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

2026-06-06 05:15:00

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan's Immunology Day on June 10 CAMBRIDGE, Mass.

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

2026-05-26 07:00:00

New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies Initial data from the first multi-dose cohort of RA study to be presented Initial data from the first multi-dose cohort of velinotamig study also to be shared Leading key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser to share clinical perspectives The Company will host the in-person event for analysts and institutional investors on Wednesday, June 10, starting at 8:30 a.m. ET in New York City CAMBRIDGE, Mass.

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

2026-05-19 07:00:00

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML

Frequently Asked Questions

What is the current Cullinan Therapeutics, Inc. (CGEM) stock price?: Cullinan Therapeutics, Inc.(NASDAQ:CGEM) stock price is $19.1 in the last trading session. During the trading session, CGEM stock reached the peak price of $19.43 while $5.68 was the lowest point it dropped to. The percentage change in CGEM stock occurred in the recent session was 4.49% while the dollar amount for the price change in CGEM stock was $0.82.
CGEM's industry and sector of operation?: The NASDAQ listed CGEM is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of CGEM?: Nadim Ahmed | President, Chief Executive Officer & Director
Jacquelyn L. Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Mary Kay Fenton | Chief Financial Officer
Rose Weldon | Senior Vice President of Corporate Affairs
Nicholas Smith | Head of Investor Relations
How many employees does CGEM have?: Number of CGEM employees currently stands at 109. CGEM operates from One Main Street, Cambridge, MA 02142, US.

Link for CGEM official website?: Official Website of CGEM is: https://cullinantherapeutics.com
How do I contact CGEM?: CGEM could be contacted at phone #617 410 4650 and can also be accessed through its website. CGEM operates from One Main Street, Cambridge, MA 02142, US.
How many shares of CGEM are traded daily?: The average number of CGEM shares traded daily for last 3 months was 933.5K.
What is the market cap of CGEM currently?: The market value of CGEM currently stands at $1.17B with its latest stock price at $19.1

Enter your email address below for free access to our Cullinan Therapeutics, Inc. (CGEM) research center and poll results.

Cullinan Therapeutics, Inc.

$19.1 USD

Company Overview

Liquidity Metrics

Sales & Valuation

Profitability

P/E Metrics

Analyst Price Target & Rating

Financial Health Scores

Key Metrics (TTM)

Company Executives

Poll Results